Objective: This paper aims to study the mapping of high-risk oncogenic Human Papilloma Virus in clients who received voluntary cervical cancer screening in five health regions of Burkina Faso. Patients and Methods: This was a multicenter and cross-sectional study with a descriptive aim which took place over a period of 25 months from July 1, 2021 to July 30, 2023. Results: Our study population consisted of 8512 clients who had taken the HPV DNA test in the health regions named Center, Center-West, Center-East, Plateau Cen
tral and Cascades in Burkina Faso. The average age of the clients was 38.03 ± 9.69 years. The overall prevalence of HR-HPV was 22.99%. The “Other HPV” serotypes were the most frequent in a proportion of 54.27%, followed by serotypes 16 and 18 respectively in 14.46% and 13.95% of cases. The prevalence of HR-HPV was 42.75% among HIV + clients. The serotypes of the “Other HPV” group (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) were the most common among clients with a precancerous cervical lesion in 57.54% of cases.
Conclusion: The health regions of Center, Center-East, Center-West, Plateau Central and Cascades in Burkina Faso have a high prevalence of HR-HPV. The
“Other HPV” serotypes were the most dominant. A further study to identify
by isolating the prevalence of the different serotypes of the “Other HPV”
DOI: 10.4236/ojog.2025.153037 Mar. 20, 2025
423
Open Journal of Obstetrics and Gynecology
T. F. D. Millogo/Traore et al.
group in these five health regions of Burkina Faso is essential to be able to
choose the most appropriate type of HPV vaccine.
Keywords
PVH-HR, Prevalence, Screening, Cancer, Cervix, Burkina Faso

PVH-HR, Prevalence, Screening, Cancer, Cervix, Burkina Faso